## A Prodrug-type, MMP-2-targeting Nanoprobe for Tumor **Detection and Imaging**

Yaping Wang, <sup>*a,b*</sup> Tingting Lin,<sup>*a,b*</sup> Wenyuan Zhang, <sup>*b*</sup> Yifan Jiang, <sup>*b*</sup> Hongyue Jin, <sup>*b*</sup> Huining He, <sup>*a*</sup> Victor C. Yang, <sup>*a,c*</sup> Yi Chen, <sup>*b*</sup> and Yongzhuo Huang \*<sup>*b*</sup>

<sup>a</sup> Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China. <sup>b</sup> Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Hai-ke, Shanghai 201203, China. Tel:

+86-21-2023-1000 ext 1401; E-mail: yzhuang@simm.ac.cn

<sup>c</sup> University of Michigan, College of Pharmacy, 428 Church St, Ann Arbor, MI 48108, USA

## **Supplementary Materials**





Figure S1. Characterization of the ALMWP-QSY (MW 3463) by HPLC (A-D) and mass spectroscopy (E).



**Figure S2**. Characterization of the QD-LMWH. (A) Fluorescence spectrum of the QD and QD-LMWH. (B) Gel electrophoresis of (a) QD, (b-d) QD-LMWH with the increasing ratio of modified LMWH. (C) TEM of the QD-LMWH. (D) Thermal gravimetric analysis of QD-LMWH (total weight loss about 11%, indicating the LMWH modification ratio).




Figure S3. Fluorescence quench caused by the formation of nanoprobe (QD-LMWH/LMWP-QSY), and quench efficiency related to the increase of the QSY amount.





Figure S4. Stability of nanoprobe in PBS or complete DMEM (containing 10% FBS). Little fluorescence activation was found in the presence or absence of serum.



**Figure S5**. Fluorescence imaging of the brain tumor cryosection (red: activated nanoprobe; blue: DAPI staining) from the mouse model with orthotopic brain tumor after tail vein injection of the nanoprobe.